AUTHOR=Ma Qing , Kong Lingping , Zhong Diansheng 

TITLE=Case Report: Dramatic Response to Crizotinib in a Patient With Non-Small Cell Lung Cancer Positive for a Novel ARL1-MET Fusion

JOURNAL=Frontiers in Oncology

VOLUME=12

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.804330

DOI=10.3389/fonc.2022.804330

ISSN=2234-943X

ABSTRACT=<p>It is imperative to know the status of oncogenic drivers in patients with non-small cell lung cancer (NSCLC). Compared with <italic>ALK</italic> and <italic>ROS1</italic> fusion, <italic>MET</italic> fusion is relatively rare in NSCLC. In this case, we report the case of a female patient with NSCLC positive for a novel <italic>ARL1-MET</italic> fusion. The patient achieved about a 5-month progression-free survival (PFS) after receiving crizotinib for unresectable right lung malignancies. To the best of our knowledge, this case provides the first clinical evidence that the novel <italic>ARL1-MET</italic> fusion might be an actionable mutation in NSCLC.</p>